Dr. Gauthier on Findings for CD19-Targeted CAR T Cells Plus Ibrutinib in CLL

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing the efficacy and toxicity of the CD19-specific chimeric antigen receptor (CAR) T-cell therapy JCAR014 alone or in combination with ibrutinib (Imbruvica) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

<<< 2018 ASH Annual Meeting

Related Content:

ASH Annual Meeting and ExpositionConferenceChronic Lymphocytic LeukemiaHematologic Oncology
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC